A Rockville immunotherapy company struck an $8 million deal to take back ownership of the drug candidates it’s been licensing ...

A dozen hedge funds, including Perceptive, Farallon, and Marshall Wace, will benefit from companies that either went public ...

Cystic fibrosis drug developer Sionna Therapeutics hopes to join the IPO wave started by Metsera and Maze Therapeutics last ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million.

Obesity-drug maker Metsera Inc.'s stock jumped 47% on Friday as the biggest gainer among three initial public offerings bucking a swoon in the equity market to rise in their stock-market debuts Friday ...

Maze Therapeutics, a clinical-stage biopharmaceutical company, launched its initial public offering (IPO) today, with shares ...

Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

(Reuters) -Shares of Maze Therapeutics rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million. The company's shares opened at $16.12 apiece, ...

Maze Therapeutics ( NASDAQ: MAZE) shares were trading largely flat following a $140M initial public offering. Shares of the kidney disease drug developer opened at $16 per share after being priced at ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.